Current status of in vitro antifungal susceptibility testing

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 8, Issue 3, 2002, Pages 110-120

  Buchta, V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BUTOCONAZOLE; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; FUNGICIDE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; SULCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL PRACTICE; COLORIMETRY; COMORBIDITY; CONTROLLED STUDY; DIFFUSION; DILUTION; DRUG PREFERENCE; DRUG RESPONSE; FUNGUS; FUNGUS ISOLATION; HUMAN; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; MEDICAL INFORMATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PREDICTION; REFERENCE VALUE; REPRODUCIBILITY; REVIEW; SIDE EFFECT; STANDARD; STANDARDIZATION; SYSTEMIC DISEASE; THRUSH; TREATMENT FAILURE; TREATMENT OUTCOME; YEAST;

EID: 0036049692     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from SENTRY Antimicrobial Surveillance Program
2. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program
3. The exciting future of antifungal therapy
4. Antifungal susceptibility testing
5. Susceptibility testing of fungi: Current status of the standardization process
6. Reference method for broth dilution antifungal susceptibility testing of yeasts
7. Reference method for broth dilution antifungal susceptibility testing of yeasts
8. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi
9. K problematice testování citlivosti oportunních původců mykóz k antimykotikům in vitro
10. In vitro anfifungal susceptibility methods and clinical implications of antifungal resistance
11. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
12. Improved medium for fluconazole susceptibility testing of Candida albicans
13. Antifungal susceptibility testing of yeasts: A brief overview
14. Fluconazole disk diffusion procedure for determining susceptibility of Candida species
15. Fluconazole disk diffusion susceptibility testing of Candida species
16. Evaluation of the susceptibility of pathogenic Candida species to fluconazole
17. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion
18. E test for antifungal susceptibility testing of yeasts
19. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing
20. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds
21. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi
22. Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates
23. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole- resistant and Candida albicans
24. Multicenter comparison of the Sensititre Yeast One colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common spp., Cryptococcus spp., and other yeasts and yeast-like organisms
25. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl- 2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method
26. Comparison of a 2,3-bis(2-Methoxy-4-nitro- 5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical clinical yeast isolates for susceptibility to antifungal agents
27. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test
28. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome
29. Quantitation of ergosterol content: Novel method for determination of fluconazole susceptibility of Candida albicans
30. Colony size can be used to determine the MIC of fluconazole for pathogenic yeasts
31. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870
32. Antifungal susceptibility testing of yeasts: Evaluation of technical variables for test automation
33. Relative inhibition factors - A novel approach to the assessment of antifungal antibiotics in vitro
34. Fluconazole susceptibility testing of Candida albicans: Microtiter method that is independent of inoculum size, temperature, and time of reading
35. Defining conditions for microbroth antifungal susceptibility tests: Influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria
36. Improved method for azole antifungal susceptibility testing
37. Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds
38. The trailing end point phenotype in antifungal susceptibility testing is ph dependent
39. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions
40. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
41. Fluconazole disk diffusion test with methylene blue- and glucose-enriched Mueller-Hinton agar for determining susceptibility of Candida species
42. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
43. Teoretické a praktické aspekty rezistence k antimykotikům
44. Detection of amphotericin B-resistant Candida isolates in a broth-based system
45. Detection of resistance to amphotericin B in Candida isolates by using Iso-Sensitest broth
46. Lot-to-lot variability of Antibiotic Medium 3 used for testing susceptibility of Candida isolates to amphotericin B
47. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae
48. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
49. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase
50. Yeast susceptibility testing: Reference methods and commercial test systems
51. Evaluation of the Fungitest kit by using strains from human immunodeficiency virus-infected patients: Study of azole drug susceptibility
52. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans
53. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome
54. Clinical utility of in vitro antifungal susceptibility testing
55. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. susceptibility testing of the National Committee for Clinical Laboratory Standards
56. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation
57. Detection of fluconazole-resistant Candida strains by a disc diffusion screening test
58. Amphotericin B-resistant yeast infection in severely immunocompromised patients
59. Correlation between in vitro susceptibility determined by Etest and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia
60. Problems in antifungal susceptibility testing
61. Antifungal pharmacodynamics: Concentration-effect relationships in vitro and in vivo